Cantor Fitzgerald Comments on Curis FY2025 Earnings

Curis, Inc. (NASDAQ:CRIS) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Curis in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the biotechnology company will post earnings of ($2.34) per share for the year. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share.

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Curis in a report on Tuesday, December 10th.

Curis Stock Down 4.7 %

NASDAQ:CRIS opened at $3.27 on Thursday. Curis has a 1 year low of $2.86 and a 1 year high of $17.49. The business has a 50 day simple moving average of $3.65 and a 200-day simple moving average of $4.75.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Curis stock. Focused Wealth Management Inc increased its position in shares of Curis, Inc. (NASDAQ:CRIS) by 63.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,066 shares of the biotechnology company’s stock after acquiring an additional 20,908 shares during the quarter. Focused Wealth Management Inc owned about 0.92% of Curis worth $291,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.